Warrior Care Panel: HBOT Across Cancer, Behavioral Health, Psychedelics, and Moral Injury
Hyperbaric oxygen therapy rebuilds it by driving oxygen into hypoxic tissue, stimulating new blood vessel growth, reducing inflammation, and reactivating neuroplasticity. Across all four panel topics, HBOT functions the same way: not as a competitor to the other modalities, but as the biological foundation the other modalities build on.
Cancer in SOF: Support Before and After Treatment
The threshold question for any oncology audience is whether added oxygen promotes tumor growth. The evidence answers that clearly. HBOT sits on both ends of the cancer timeline: relieving the tumor hypoxia that drives radiation resistance, and healing the collateral tissue damage that radiotherapy leaves behind.
Hyperbaric Oxygen Therapy and Cancer: A Review
Moen I, Stuhr LEB. (2012). Targeted Oncology
Review of the preclinical and clinical literature on HBOT in malignancy. Two prior systematic reviews concluded that HBOT is safe in patients with cancer, with no evidence that it acts as a stimulator of tumor growth or an enhancer of recurrence. In certain tumor subtypes the evidence points to a tumor-inhibitory effect. This is the reference that neutralizes the single most common objection to HBOT in oncology.
Hyperbaric Oxygen Therapy for Managing Cancer Treatment Complications: A Safety Evaluation
Canarslan Demir K, et al. (2025). Medicina
Retrospective safety analysis of patients with active or previously treated solid tumors who received HBOT. HBOT administered after radiation therapy was not associated with increased risk of recurrence or metastasis, and no tumor progression was observed in the treated cohort. Confirms that HBOT can be used to manage treatment-related complications without compromising oncologic safety.
Oscarsson N, et al. (2019). The Lancet Oncology
Randomized, controlled phase 2-3 trial across five Nordic university hospitals in patients with late radiation cystitis after pelvic cancer radiotherapy. HBOT significantly improved symptoms versus standard care, with the EPIC urinary total score improving by roughly 10 points. This is the strongest RCT-level evidence for HBOT in the treatment of radiation tissue injury, a UHMS-approved indication.
Hyperbaric Oxygen Therapy in Glioma and Brain Metastasis: Radiosensitization and Neuroprotection
Cai T. (2025). Medical Gas Research
Review addressing both ends of the value proposition. HBOT relieves tumor hypoxia and enhances radiosensitivity, since hypoxic tumor cells are markedly more radiation-resistant than normoxic cells. On the back end, HBOT provides neuroprotection against radiation-induced brain injury after stereotactic radiosurgery and supports neurological recovery. Positions HBOT as relevant at two distinct points in the cancer care continuum.
Synthesis: HBOT does not feed cancer. The safety literature is consistent on that point. What it does is improve the therapeutic ratio of radiation on the front end and treat the radiation injuries that degrade quality of life on the back end, from cystitis and proctitis to osteoradionecrosis and soft-tissue necrosis. For an operator population that will face these treatments, HBOT belongs in the supportive-care conversation.
Behavioral Health: Getting the Brain Ready for the Work
CBT, DBT, and ACT all operate through neuroplasticity, asking the brain to build new patterns and regulate emotion. That process requires a brain with oxygen, perfusion, and connectivity to do the work. In blast-exposed and trauma-affected operators, imaging shows that substrate is compromised in exactly the circuits these therapies target. HBOT restores it, which is why it belongs before and alongside behavioral health care rather than in competition with it.
Doenyas-Barak K, et al. (2024). Journal of Clinical Psychiatry
Randomized, sham-controlled trial in combat veterans with treatment-resistant PTSD. HBOT produced a significant reduction in CAPS-5 score versus sham, sustained at three-month follow-up, with fMRI and DTI confirming restored fronto-limbic activity and white matter integrity. Critically, HBOT was delivered as one integrated protocol alongside psychologists and psychiatrists, not as a replacement for them, and reached patients who had already failed medication and psychotherapy.
Doenyas-Barak K, et al. (2022). PLoS ONE
RCT in combat veterans with treatment-resistant PTSD showing a large-magnitude improvement in PTSD severity (effect size 1.64) in patients who had failed both medication and therapy. DTI demonstrated structural white matter repair in the fronto-limbic tracts that govern emotional regulation, the same circuitry behavioral health treatment is trying to reach.
Synthesis: These therapies ask the brain to change. HBOT makes it physically capable of changing by restoring the perfusion, oxygenation, and connectivity that plastic change depends on. The behavioral health work then goes further and lasts longer. The largest combat-PTSD program in the world delivered HBOT and mental-health care together for exactly this reason.
Psychedelics Research: A Parallel Neuroplasticity Modality
HBOT and psychedelics reach the same biological endpoint through different routes. No published trials have combined the two, but the science points to a shared final pathway: neuroplasticity. Psychedelics open a plasticity window from the top down through the serotonin system. HBOT prepares the tissue from the bottom up by restoring the blood flow and oxygenation that plastic change physically requires.
HBOT Induces Cerebral Angiogenesis and Nerve Fiber Regeneration in Chronic TBI
Tal S, Hadanny A, Sasson E, Suzin G, Efrati S. (2017). Frontiers in Human Neuroscience
Imaging study showing HBOT induces cerebral angiogenesis with increased perfusion to chronically damaged brain tissue, and DTI-confirmed regeneration of nerve fibers, months to years after injury. This establishes the mechanism by which HBOT restores the vascular and structural substrate that any neuroplasticity-based intervention, including psychedelic-assisted therapy, ultimately acts upon.
de Vos CMH, Mason NL, Kuypers KPC. (2021). Frontiers in Psychiatry
Systematic review of the mechanism behind psychedelic therapy. A single administration produces rapid changes in plasticity at the molecular, synaptic, and dendritic level, including altered BDNF expression and dendritic growth that outlasts the acute drug effect. Included here as panel context: it defines the neuroplasticity endpoint that HBOT reaches through a different, vascular mechanism, making the two modalities complementary in principle.
Synthesis: Both modalities drive neuroplasticity through different mechanisms. HBOT rebuilds the vascular and structural tissue; psychedelics open the plasticity window. The combination is unstudied, but the biology suggests HBOT is a rational first step to prepare the brain that psychedelic therapy acts on.
Moral Injury Mitigation: Healing the Inflamed Brain Beneath the Wound
Moral injury is a wound to conscience and meaning, the guilt, shame, and loss of trust that follow events that violate a warrior’s moral code. It is healed through moral and spiritual work: Adaptive Disclosure, Acceptance and Commitment Therapy, and Building Spiritual Strength. What HBOT does is clear the physical barrier that keeps so many warriors from being able to do it.
Moral injury almost never arrives alone. The same combat exposure that causes it also causes traumatic brain injury and PTSD, and those are physical, inflammatory injuries to the brain. TBI and PTSD drive chronic neuroinflammation and reduced blood flow in the prefrontal cortex and limbic system, the exact regions that govern emotional regulation, memory, and self-compassion. A brain locked in that inflamed, oxygen-starved state cannot fully engage in the emotional processing that moral recovery demands. HBOT targets that biology head-on. It lowers the pro-inflammatory signaling that damages brain tissue, floods hypoxic regions with oxygen, restores blood flow, and reactivates repair in the injured circuits.
Hyperbaric Oxygen Inhibits Stimulus-Induced Proinflammatory Cytokine Synthesis
Benson RM, Minter LM, Osborne BA, Granowitz EV. (2003). Clinical & Experimental Immunology
Demonstrates the anti-inflammatory mechanism at the cellular level. A single 90-minute HBOT exposure reduced production of the key pro-inflammatory cytokines that drive tissue damage, cutting IL-1 beta by up to 68% and TNF-alpha by up to 62%. These are the same inflammatory mediators elevated in TBI and PTSD. This is the biological basis for HBOT calming the neuroinflammation that keeps an injured brain from healing and from doing the work of moral recovery.
The result is a warrior who walks into moral-injury therapy with a brain that is finally ready. The combat-PTSD and chronic-TBI evidence in the Behavioral Health section above shows this same brain repair on imaging: restored fronto-limbic function, rebuilt white matter, and measurable cognitive recovery.
Synthesis: Moral injury is healed by moral repair. But most warriors carrying it are also carrying an inflamed, blast-injured brain that blocks the path. HBOT calms that inflammation and restores the neurological foundation, so the moral and spiritual work these programs deliver can finally take hold. HBOT does not compete with moral-injury care. It makes it possible.